Central Retinal Venous Occlusion Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Central Retinal Venous Occlusion Epidemiology Forecast Report Coverage

Expert Market Research's “Central Retinal Venous Occlusion Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of central retinal venous occlusion. It projects the future incidence and prevalence rates of central retinal venous occlusion cases across various populations.  The study covers age, gender, and type as major determinants of the central retinal venous occlusion population. The report highlights patterns in the prevalence of central retinal venous occlusion over time and projects future trends based on multiple variables.

Central Retinal Venous Occlusion Understanding: Disease Overview

Central retinal venous occlusion (CRVO) occurs when the main vein draining blood from the retina becomes blocked, usually due to a blood clot, reflecting a distinct ocular vascular obstruction pattern. This blockage leads to impaired blood flow, causing retinal swelling, hemorrhages, and vision problems. Risk factors include high blood pressure, diabetes, glaucoma, and clotting disorders. Symptoms often include sudden, painless vision loss or blurring in one eye. CRVO is classified as non-ischemic or ischemic, with the latter posing a higher risk of severe vision loss. Treatment includes managing underlying conditions, anti-VEGF injections, or laser therapy to reduce complications.

Central Retinal Venous Occlusion Epidemiology Perspective

The central retinal venous occlusion epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the central retinal venous occlusion epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for central retinal venous occlusion and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to the National Institute for Health and Care Excellence, CRVO is slightly more common in males and occurs in over 90% of individuals aged above 50 years. However, cases are reported in all age groups, reflecting an age-related retinal vascular risk pattern with no clear racial preference. 
• As per Kyle Blair, et al., 2023, non-ischemic CRVO resolves completely in approximately 10% of cases, while 50% of patients experience vision of 20/200 or worse, and around one-third progress to ischemic CRVO, indicating a distinct CRVO progression profile within 6–12 months. 
• According to Steven Baker  et al., 2024, retinal vein occlusion may develop in the fellow eye in 7% of cases within two years, with a 4-year risk of 2.5% in the same eye and 11.9% in the fellow eye, highlighting bilateral involvement risk trends in disease course. 
• Hypertension, present in 73% of patients over 50 and 25% of younger patients, as determined by Estefania Oliveros, et al., 2019, significantly increases the risk of recurrence in either eye, reflecting a strong cardiovascular-associated ocular risk pattern.

Read more about this report - Request a Free Sample

Country-wise Central Retinal Venous Occlusion Epidemiology

The central retinal venous occlusion epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of central retinal vein occlusion (CRVO) varies globally, being the second most common retinal vascular disorder, reflecting a distinct CRVO prevalence pattern. Non-ischemic CRVO is more prevalent than the ischemic type. According to Christina J. Flaxel, et al., 2020, in East Asia and the United States,pooled data indicate RVO affects 0.8 per 100ls. The Beaver Dam Eye Study reported a 15-year cumulative incidence of 0.5%.

Central Retinal Venous Occlusion: Treatment Overview

Central retinal vein occlusion (CRVO) treatment aims to manage complications, improve vision, and prevent progression, reflecting evolving CRVO treatment outcome patterns in clinical care. Management includes anti-vascular endothelial growth factor (VEGF) injections, corticosteroids, and addressing risk factors like hypertension and diabetes to reduce recurrence or bilateral involvement. Corticosteroid implants may also be employed in specific cases. Managing underlying risk factors, such as hypertension, diabetes, and glaucoma, is critical to reducing recurrence and preventing bilateral involvement.

Key Questions Answered

• What are the key findings of central retinal venous occlusion epidemiology in the 8 major markets?
• What will be the total number of patients with central retinal venous occlusion across the 8 major markets during the forecast period?
• What was the country-wise central retinal venous occlusion epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of central retinal venous occlusion patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of central retinal venous occlusion during the forecast period of 2026-2035?
• What are the currently available treatments for central retinal venous occlusion?
• What are the disease risks, signs, symptoms, and unmet needs of central retinal venous occlusion?

Scope of the Central Retinal Venous Occlusion Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of central retinal venous occlusion based on several factors.
• Central Retinal Venous Occlusion Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The central retinal venous occlusion report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Glaucoma Therapeutics Market

Eye Care Market